ACTIVITY OF CYTOSTATIC DRUGS IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR CANCER CELL-LINES WITH DIFFERENT SENSITIVITY TO STANDARD AGENTS

被引:11
作者
HARSTRICK, A
SCHMOLL, HJ
CASPER, J
WILKE, H
POLIWODA, H
机构
[1] Department of Hematology and Oncology, University of Hannover Medical School, 3000 Hannover 61
关键词
D O I
10.1016/0277-5379(90)90195-Y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two established human testicular cancer cell lines were used in a mouse xenograft model to assess the antitumour activity of 15 anticancer agents. Line H 12.1 was highly sensitive to cisplatin, bleomycin and vinblastine, resembling non-pretreated testicular tumours, whereas line H 23.1 showed resistance to cisplatin and vinblastine, comparable to tumours with acquired or intrinsic drug resistance. In line H 12.1 several drugs were highly active, including cyclophosphamide, ifosfamide, nimustine and vincristine; carmustine, vindesine, doxorubicin, epidoxorubicin, pirarubicin, mitoxantrone, carboplatin and iproplatin had only moderate activity. In line H 23.1 only cyclophosphamide, ifosfamide, nimustine, vincristine and bleomycin had antitumour activity. These two cell lines represent a useful model for preclinical evaluation of new agents with presumed activity in testis cancer. © 1990.
引用
收藏
页码:898 / 901
页数:4
相关论文
共 21 条
  • [1] VAB-6 - AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR PATIENTS WITH GERM-CELL TUMORS
    BOSL, GJ
    GLUCKMAN, R
    GELLER, NL
    GOLBEY, RB
    WHITMORE, WF
    HERR, H
    SOGANI, P
    MORSE, M
    MARTINI, N
    BAINS, M
    MCCORMACK, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (10) : 1493 - 1499
  • [2] ALTERNATING CYCLES OF ETOPOSIDE PLUS CISPLATIN AND VAB-6 IN THE TREATMENT OF POOR-RISK PATIENTS WITH GERM-CELL TUMORS
    BOSL, GJ
    GELLER, NL
    VOGELZANG, NJ
    CAREY, R
    AUMAN, J
    WHITMORE, WF
    HERR, H
    MORSE, M
    SOGANI, P
    CHAN, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) : 436 - 440
  • [3] BUCKNER CD, 1974, CANCER CHEMOTH REP 1, V58, P709
  • [4] Fiebig H H, 1984, Behring Inst Mitt, P343
  • [5] HASTRICK A, 1989, CANCER, V63, P1079
  • [6] GROWTH-CHARACTERISTICS OF HUMAN COLORECTAL TUMORS DURING SERIAL PASSAGE IN IMMUNE-DEPRIVED MICE
    HOUGHTON, JA
    TAYLOR, DM
    [J]. BRITISH JOURNAL OF CANCER, 1978, 37 (02) : 213 - 223
  • [7] CYCLIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN PLUS VINBLASTINE AND BLEOMYCIN IN ADVANCED GERMINAL TUMORS - RESULTS WITH 100 PATIENTS
    LOGOTHETIS, CJ
    SAMUELS, ML
    SELIG, DE
    OGDEN, S
    DEXEUS, F
    SWANSON, D
    JOHNSON, D
    VONESCHENBACH, A
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) : 219 - 228
  • [8] OZOLS RF, 1988, CLIN ONCOL, V6, P486
  • [9] ROTH BJ, 1988, SEMIN ONCOL, V15, P345
  • [10] CIS-DIAMMINEDICHLOROPLATINUM(II) - NEW ANTICANCER DRUG
    ROZENCWEIG, M
    VONHOFF, DD
    SLAVIK, M
    MUGGIA, FM
    [J]. ANNALS OF INTERNAL MEDICINE, 1977, 86 (06) : 803 - 812